These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 36269898)

  • 21. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
    Rodriguez-Otero P; Ailawadhi S; Arnulf B; Patel K; Cavo M; Nooka AK; Manier S; Callander N; Costa LJ; Vij R; Bahlis NJ; Moreau P; Solomon SR; Delforge M; Berdeja J; Truppel-Hartmann A; Yang Z; Favre-Kontula L; Wu F; Piasecki J; Cook M; Giralt S
    N Engl J Med; 2023 Mar; 388(11):1002-1014. PubMed ID: 36762851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cilta-cel OK'd for Multiple Myeloma.
    Cancer Discov; 2022 May; 12(5):1176. PubMed ID: 35491644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma.
    Martin T; Krishnan A; Yong K; Weisel K; Mehra M; Nair S; Qi K; Londhe A; Diels J; Crivera C; Jackson CC; Olyslager Y; Vogel M; Schecter JM; Banerjee A; Valluri S; Usmani SZ; Berdeja JG; Jagannath S
    EJHaem; 2022 Feb; 3(1):97-108. PubMed ID: 35846215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety assessment of anti-B cell maturation antigen chimeric antigen receptor T cell therapy: a real-world study based on the FDA adverse event reporting system database.
    Liu W; Lin S; Zhu X; Yin L; Liu Q; Lei S; Feng B
    Front Immunol; 2024; 15():1433075. PubMed ID: 39290710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma.
    Zhao WH; Liu J; Wang BY; Chen YX; Cao XM; Yang Y; Zhang YL; Wang FX; Zhang PY; Lei B; Gu LF; Wang JL; Yang N; Zhang R; Zhang H; Shen Y; Bai J; Xu Y; Wang XG; Zhang RL; Wei LL; Li ZF; Li ZZ; Geng Y; He Q; Zhuang QC; Fan XH; He AL; Zhang WG
    J Hematol Oncol; 2018 Dec; 11(1):141. PubMed ID: 30572922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparison.
    Bar N; Diels J; van Sanden S; Mendes J; Hernando T; Burnett H; Cost P; Schecter JM; Lendvai N; Patel N; Ishida T; Er J; Harrison SJ; Lopez-Muñoz N
    Curr Med Res Opin; 2024 Sep; 40(9):1597-1603. PubMed ID: 39129504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma.
    Hansen DK; Dhakal B; Hamadani M; Dingli D; Jain T; Huff CA; Janakiram M; Liu YH; De Braganca KC; Lodowski N; Sander J; Okorozo P; McFarland L; Perciavalle M; Huo S; Qureshi ZP; Patel KK
    Front Immunol; 2024; 15():1405452. PubMed ID: 38915401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report.
    Wang BY; Zhao WH; Chen YX; Cao XM; Yang Y; Zhang YL; Wang FX; Zhang PY; Lei B; Gu LF; Wang JL; Bai J; Xu Y; Wang XG; Zhang RL; Wei LL; Zhuang QC; Fan F; Zhang WG; He AL; Liu J
    J Med Case Rep; 2022 Dec; 16(1):459. PubMed ID: 36496425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study.
    Cohen AD; Hari P; Htut M; Berdeja JG; Usmani SZ; Madduri D; Olyslager Y; Goldberg JD; Schecter JM; Jackson CC; Gries KS; Fastenau JM; Valluri S; Deraedt W; Akram M; Crawford R; Morrison R; Doward L; Morgan K; Seldam ST; Jakubowiak A; Jagannath S
    Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):68-77. PubMed ID: 36357295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
    Martin T; Usmani SZ; Schecter JM; Roccia T; Jackson CC; Deraedt W; Yeh TM; Banerjee A; Pacaud L; Garrett A; Bartlett M; Haltner A; Van Sanden S; Diels J; Valluri S; Samjoo IA
    Curr Med Res Opin; 2023 Jan; 39(1):81-89. PubMed ID: 36271807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma.
    Fang J; Zhou F
    Ann Hematol; 2024 Apr; 103(4):1069-1083. PubMed ID: 37704875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plain language summary of the CARTITUDE-4 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma.
    San-Miguel J; Dhakal B; Patel N; Schecter JM; Lendvai N; Einsele H
    Future Oncol; 2024; 20(33):2509-2520. PubMed ID: 39110421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma.
    Wesson W; Dima D; Suleman N; Saif MSI; Tabak C; Logan E; Davis JA; McGann M; Furqan F; Mohan M; Rashid A; Abdallah AO; Ullah F; Shune L; Mushtaq MU; Raza S; McGuirk J; Hamadani M; Anwer F; Hashmi H; Ahmed N
    Transplant Cell Ther; 2024 Sep; 30(9):876-884. PubMed ID: 38871056
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.
    Que Y; Xu M; Xu Y; Almeida VDF; Zhu L; Wang Z; Wang Y; Liu X; Jiang L; Wang D; Li C; Zhou J
    Front Immunol; 2021; 12():755866. PubMed ID: 34777368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The characteristics and impact on prognosis of cytopenia after anti-BCMA-CAR-T therapy in patients with relapsed and refractory multiple myeloma].
    Shen XX; Yao Y; Xia Y; Jin YY; Zhang R; Li JY; Chen LJ
    Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(7):507-513. PubMed ID: 38317362
    [No Abstract]   [Full Text] [Related]  

  • 36. FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma.
    Natrajan K; Kaushal M; George B; Kanapuru B; Theoret MR
    Clin Cancer Res; 2024 Jul; 30(14):2865-2871. PubMed ID: 38713595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
    Raje N; Berdeja J; Lin Y; Siegel D; Jagannath S; Madduri D; Liedtke M; Rosenblatt J; Maus MV; Turka A; Lam LP; Morgan RA; Friedman K; Massaro M; Wang J; Russotti G; Yang Z; Campbell T; Hege K; Petrocca F; Quigley MT; Munshi N; Kochenderfer JN
    N Engl J Med; 2019 May; 380(18):1726-1737. PubMed ID: 31042825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
    Anderson LD; Dhakal B; Jain T; Oluwole OO; Shah GL; Sidana S; Perales MA; Pasquini MC
    Transplant Cell Ther; 2024 Jan; 30(1):17-37. PubMed ID: 37913909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma.
    Weisel K; Krishnan A; Schecter JM; Vogel M; Jackson CC; Deraedt W; Yeh TM; Banerjee A; Yalniz F; Nesheiwat T; Van Sanden S; Diels J; Valluri S; Usmani SZ; Berdeja JG; Jagannath S; Martin T
    Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):690-701. PubMed ID: 35764490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.
    Yang J; Zhou W; Li D; Niu T; Wang W
    Cancer Lett; 2023 Jan; 553():215949. PubMed ID: 36216149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.